Abbott Laboratories
ABTHealthcareNASDAQMedical Devices · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. At a $175.37B market cap, Abbott Laboratories ranks as a large-cap company within healthcare. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Market Cap
$175.37B
Beta
0.61
P/E (TTM)
27.74
P/E (Fwd)
16.60
EPS (TTM)
$3.63
EPS (Fwd)
$6.07
ROE
12.3%
ROA
5.6%
Cash
$7.30B
Total Debt
$34.14B
Free CF
$6.34B
52W Change
-18.6%
Annual Financials
Cash vs Debt
On the balance sheet, ABT has $7.30B in cash with $34.14B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $6.34B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 12.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $43.65B (2022) to $44.33B (2025).
With a beta below 0.7, Abbott Laboratories typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing ABT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.